Keytruda improves survival in first-line squamous NSCLC

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab plus chemotherapy met the primary endpoints of improving progression-free survival (PFS) and overall survival (OS)

Read the full 230 word article

User Sign In